Monitoring esophageal transit of wax-polished alendronate in healthy postmenopausal women: A new technique for the study of pill transit time

Current Therapeutic Research - Clinical and Experimental

Volumn 63, Issue 2, 2002, Pages 103-109

  Drake, William M ^a,b   Worsley, Daniel F ^a   Lentle, Brian C ^a   Kendler, David L ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b William M Drake Osteoporosis Research Centre   (Canada)

Author keywords

Bisphosphonate; Esophageal transit; Esophagitis

Indexed keywords

ALENDRONIC ACID; PERTECHNETIC ACID TC 99M;

ADULT; AGED; ARTICLE; DRUG COATING; DRUG MARKETING; DRUG TRANSPORT; ESOPHAGITIS; ESOPHAGUS DISEASE; FEMALE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; OSTEOPOROSIS; PILL; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 0036197088     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(02)80010-8     Document Type: Article

References (22)

1. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the fracture intervention trial
2. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
3. Skeletal benefits of alendronate: 7-Year treatment of postmenopausal osteoporotic women
4. Alendronate in the treatment of osteoporosis: A review of the clinical trials
5. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
6. Upper gastrointestinal tract safety profile of alendronate: The Fracture Intervention trial
7. Esophagitis associated with the use of alendronate
8. Multiple ulcerative esophagitis caused by alendronate
9. A new probable increasing cause of esophageal irritation: Alendronate
10. Medication-induced esophageal injury: Report of 17 cases with endoscopic documentation
11. "Pill esophagitis" - The case of alendronate
12. Pamidronate: An unrecognized problem in gastrointestinal tolerability
13. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
14. Risedronate is an effective and well-tolerated therapy in both the treatment and prevention of corticosteroid-induced osteoporosis
15. Risedronate prevents bone loss and decreases the risk of vertebral fractures in corticosteroid-induced osteoporosis
16. Drug induced esophageal damage: Diseases of medical progress
17. The effect of size and shape of tablets on their esophageal transit
18. Factors influencing the transit of a gelatin capsule in the esophagus
19. Esophageal scintigraphy to quantitate esophageal transit (quantitation of esophageal transit)
20. Radionuclide transit studies in the detection of oesophageal dysmotility
21. Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulations
22. Esophageal scintigraphy: Reproducibility and normal ranges